PPT-SGLT2 Inhibitors and Their Clinical Impact:

Ominous Octet Renal Handling of Glucose Active SGLT2 and Passive GLUT2 Glucose Transport in a Renal Proximal Tubule Cell Renal Glucose Transport GLUTs Altered Renal Glucose Control in T2D. Newly Approved Drug to Lower HbA1C in Type-2 diabetes. Presented By: . Rahul Patel,. . MS, PharmD. . C. andidate 2015. Dr. Sam Shimomura, Associate Dean,. Western University of Health Sciences . . Inhibitors. anodic inhibitors. : . p. hosphates. s. ilicate . c. ompounds. . Cathodic inhibitors. poly-p. hosphates. . Ca(HCO3)2. methylamino-phosphate. (c). . mixed anodic and cathodic inhibitors. Expert Panelists. Program Goals. Evaluating CV Risk in New Antidiabetic Therapies. FDA Guidance. EXAMINE and SAVOR-TIMI 53. EXAMINE. New Analyses. SAVOR-TIMI 53. Saxagliptin in . Patients With T2D and History of/at Risk for CV Events. Program Goals. Complementary Mechanism of Action . . DPP-4 Inhibitors SGLT2 Inhibitors . Clinical Pearls. Fixed-Dose Combination Therapies. Using Fixed-Dose Combination Therapies to Achieve HbA. 1c. IL-17 Inhibitors in the Management of Psoriatic Disease . Agenda. Treat-to-Target in PsA. Early Intervention and Tight Control of Inflammation in Patients With PsA: TICOPA . MDA Criteria. TICOPA: Commonly Reported AEs. Pan Tumors. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. This program will include a discussion of off-label treatment and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Diabetes Drugs Have Been Shown to Reduce CV Risk. CDK 4/6 Inhibitors in Breast Cancer Expert Perspectives on New Data Faculty Javier Cortes, MD, PhD Head Breast Cancer Program Oncology Department Ramon y Cajal University Hospital Madrid, Spain Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors Introduction/Overview Intensive Therapy Reduces Diabetes Complications Rates Variability in Time-Action Profile of Basal Insulins* Department of Endocrinology and Diabetes, . Saitama Medical Center, Saitama Medical University. 松田　昌文　. Matsuda, . Masafumi. 2018. 年. 5. 月. 23. 日　. 8:30-8:55. ４階　カンファレンス室. Oral hypoglycemics. Factors to consider:. Cost. Availability. Side effects. Tolerability. Risk. Accessory benefits. metformin. Metformin is the . preferred initial pharmacologic agent . for the treatment of type 2 diabetes. . Antidiabetes. Medications:. Cardiovascular Benefits. Hengameh. . Abdi. Endocrine Research Center. Research Institute for Endocrine sciences. Shahid. . Beheshti. University of Medical Sciences. 13 December 2018. Dr Theingi Aung. Endocrinologist. Royal Berkshire Hospital. 12. th. Jan 2018. What would your ideal diabetes drug do?. Effective in lowering HbA1c. No . hypoglycaemia. No effect on weight/ weight loss?. “old” chemosensitizers, “new” immune-sensitizers. Martina Godel. SIC Conference – Virtual Event. 27. th. -28. th.  October 2021. 1. P-. glycoprotein. and . resistance. to . chemotherapy.